While fundamentals show increased losses, the substantial cash improvement and non-dilutive funding reduce near-term dilution risk. Multiple 2026 clinical catalysts (ARDS, GVHD, IPF) could drive value inflection; traders should monitor trial initiations and data readouts as key triggers.
INKT drugs
INKT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $10.53entry
- T+1 · 8mo ago +0.38%α −0.37% · $10.57
- T+5 · 7mo ago +5.89%α +1.94% · $11.15
- T+20 · 7mo ago +4.61%α −4.82% · $11.02
- T+60 · 5mo ago +10.54%α −1.84% · $11.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss increase to $12.5M but improved cash position of $13.4M, supported by non-dilutive funding and a recent $3M raise. The company emphasized pipeline progress, including upcoming Phase 2 trials in ARDS and GVHD, with multiple clinical catalysts expected in 2026.
Key Financial Metrics
Key Facts
- Net loss for FY 2025 was $12.5 million, up from $10.8 million in 2024.
- Cash and cash equivalents totaled $13.36 million as of December 31, 2025, up from $4.58 million in 2024.
- Raised additional $3.0 million post-year-end via at-the-market offering, extending cash runway into 2026.
- Phase 2 trial for agenT-797 in ARDS to initiate in 1H 2026, with early data expected by year-end.
- GVHD program fully funded by NIH grant and philanthropic award, with first dosing expected May 2026.
- C-Further Consortium collaboration provides up to $1.1 million in non-dilutive funding plus revenue share for PRAME-TCR iNKT program.
Financial Impact
Net loss increased 15.7% YoY to $12.5M; cash position improved by $8.78M; $3M raised post-period; $1.1M non-dilutive funding secured.
Risk Factors
- Continued net losses may pressure valuation if clinical milestones are delayed.
- Reliance on external funding for GVHD program creates execution risk if trial timelines slip.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265350 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers